These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36848033)

  • 1. Nasal sprays for treating COVID-19: a scientific note.
    Chavda VP; Baviskar KP; Vaghela DA; Raut SS; Bedse AP
    Pharmacol Rep; 2023 Apr; 75(2):249-265. PubMed ID: 36848033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.
    Chavda VP; Vora LK; Pandya AK; Patravale VB
    Drug Discov Today; 2021 Nov; 26(11):2619-2636. PubMed ID: 34332100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19.
    Chavda VP; Patel AB; Vora LK; Singla RK; Shah P; Uversky VN; Apostolopoulos V
    Curr Pharm Des; 2022; 28(46):3658-3670. PubMed ID: 36284382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.
    Ramasamy R
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial.
    Lin Y; Yue S; Yang Y; Yang S; Pan Z; Yang X; Gao L; Zhou J; Li Z; Hu L; Tang J; Wu Q; Lei S; Tian Q; Wang Y; Hao Y; Xu L; Huang Q; Zhu B; Chen Y; Chen X; Ye L
    Clin Infect Dis; 2023 Feb; 76(3):e336-e341. PubMed ID: 35666466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
    Kehagia E; Papakyriakopoulou P; Valsami G
    Vaccine; 2023 Jun; 41(24):3589-3603. PubMed ID: 37179163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasal vaccine as a booster shot: a viable solution to restrict pandemic?
    Meenakshi S; Kumar VU; Dhingra S; Murti K
    Clin Exp Vaccine Res; 2022 May; 11(2):184-192. PubMed ID: 35799869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerical evaluation of spray position for improved nasal drug delivery.
    Basu S; Holbrook LT; Kudlaty K; Fasanmade O; Wu J; Burke A; Langworthy BW; Farzal Z; Mamdani M; Bennett WD; Fine JP; Senior BA; Zanation AM; Ebert CS; Kimple AJ; Thorp BD; Frank-Ito DO; Garcia GJM; Kimbell JS
    Sci Rep; 2020 Jun; 10(1):10568. PubMed ID: 32601278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.
    Dhama K; Dhawan M; Tiwari R; Emran TB; Mitra S; Rabaan AA; Alhumaid S; Alawi ZA; Al Mutair A
    Hum Vaccin Immunother; 2022 Nov; 18(5):2045853. PubMed ID: 35258416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
    Tiboni M; Casettari L; Illum L
    Int J Pharm; 2021 Jun; 603():120686. PubMed ID: 33964339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral and intranasal vaccines against SARS-CoV-2: Current progress, prospects, advantages, and challenges.
    Kar S; Devnath P; Emran TB; Tallei TE; Mitra S; Dhama K
    Immun Inflamm Dis; 2022 Apr; 10(4):e604. PubMed ID: 35349752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
    Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
    J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of Agarose-aided Sprays to the Posterior Nose for Mucosa Immunization and Short-term Protection against Infectious Respiratory Diseases.
    Seifelnasr A; Talaat M; Si XA; Xi J
    Curr Pharm Biotechnol; 2024; 25(6):787-798. PubMed ID: 37533243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID.
    Jessop ZM; Gibson J; Lim JY; Jovic TH; Combellack E; Dobbs TD; Carter K; Hiles S; Islam S; Healy B; Humphreys I; Eccles R; Hutchings HA; Whitaker IS
    Trials; 2022 Sep; 23(1):782. PubMed ID: 36109791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
    Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model.
    Errecalde J; Lifschitz A; Vecchioli G; Ceballos L; Errecalde F; Ballent M; Marín G; Daniele M; Turic E; Spitzer E; Toneguzzo F; Gold S; Krolewiecki A; Alvarez L; Lanusse C
    J Pharm Sci; 2021 Jun; 110(6):2501-2507. PubMed ID: 33493479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.